Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 210 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacogenetics Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacogenomics and Post-Operative Nausea and Vomiting

NCT03503292
View directory record Official record
Conditions
Postoperative Nausea
Interventions
Granisetron, Ondansetron
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 21, 2026, 5:32 PM EDT
Completed No phase listed Observational

Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants

NCT00360256
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 21, 2026, 5:32 PM EDT
Not listed Phase 3 Interventional

Pharmacogenetics for Pain Management in Joint Replacement Patients

NCT03772535
View directory record Official record
Conditions
Arthroplasty Complications
Interventions
Pharmacogenomics Testing
Diagnostic Test
Lead sponsor
Anderson Orthopaedic Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 21, 2026, 5:32 PM EDT
Active, not recruiting Not applicable Interventional

An Evaluation of the Impact of Pharmacist Personalized Medication Reviews With and Without a Discussion of Pharmacogenomic Results in an Employee Health Program.

NCT06660264
View directory record Official record
Conditions
Pharmacogenetics, Pharmacogenomic Drug Interaction
Interventions
Pharmacist Personalized Medication Review (PMR), Discussion of Pharmacogenomic results during the PMR
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clopidogrel Pharmacogenetics (PGX) Bench to Bedside

NCT01341600
View directory record Official record
Conditions
Metabolism of Clopidogrel
Interventions
Clopidogrel, Omeprazole/Clopidogrel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 21, 2026, 5:32 PM EDT
Withdrawn Not applicable Interventional

Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans

NCT04893395
View directory record Official record
Conditions
Pharmacogenetics, Depressive Disorder, Major, Medication Therapy Management
Interventions
Pharmacogenomic Screening
Other
Lead sponsor
Auburn University
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 21, 2026, 5:32 PM EDT
Completed No phase listed Observational Results available

Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population

NCT03468309
View directory record Official record
Conditions
Pharmacogenetic Testing
Interventions
Genecept Assay and G-DIG decision tool
Genetic
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Genetics on Metabolism of Efavirenz

NCT00245986
View directory record Official record
Conditions
Metabolism
Interventions
Blood draw
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 55 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 5:32 PM EDT
Terminated Not applicable Interventional

Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures

NCT02599870
View directory record Official record
Conditions
Acute Pain, Surgery
Interventions
NeuroIDgenetix Test Panel
Genetic
Lead sponsor
AltheaDx
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 21, 2026, 5:32 PM EDT
Completed No phase listed Observational

Pharmacogenomics and Effective Treatment With Clopidogrel

NCT01611545
View directory record Official record
Conditions
Pharmacogenomics and Cardiovascular Events
Interventions
Pharmacogenomics
Genetic
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 21, 2026, 5:32 PM EDT
Active, not recruiting Not applicable Interventional

Evaluating Microarray Pharmacogenetic Testing in Cancer Patients

NCT06489041
View directory record Official record
Conditions
Cancer, Gastrointestinal Cancer
Interventions
Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx"
Genetic
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Not applicable Interventional Results available

Integrating Pharmacogenetics In Clinical Care

NCT02871934
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
SLCO1B1 Genotype
Genetic
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 75 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Not applicable Interventional

A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"

NCT00334464
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Standard of care or genotyping dosing of warfarin dosing
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 21, 2026, 5:32 PM EDT
Completed No phase listed Observational

Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy

NCT05583422
View directory record Official record
Conditions
Cancer
Interventions
DPYD or UGT1A1 variants
Genetic
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 21, 2026, 5:32 PM EDT
Completed No phase listed Observational

Relative Effectiveness of Schizophrenia Therapy Study

NCT01245348
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
SULT4A1-1 genetic test
Genetic
Lead sponsor
Medco Health Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Franklin Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 21, 2026, 5:32 PM EDT
Enrolling by invitation Not applicable Interventional

Comprehensive Assessment of Reactions to Pharmacogenetics in Complex Care Patients

NCT07060300
View directory record Official record
Conditions
Pediatric Medical Complexity Based on PMCA Score of 3
Interventions
Agree to Pharmacogenetic Testing
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Response to Anti-hypertensives in Pregnant and Postpartum Patients

NCT03506724
View directory record Official record
Conditions
Hypertension in Pregnancy, Preeclampsia
Interventions
Nifedipine, Labetalol
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers

NCT02371889
View directory record Official record
Conditions
Alcoholism, Alcohol Use Disorder (AUD)
Interventions
Topiramate, Medical Management, Inactive Placebo
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 21, 2026, 5:32 PM EDT
Recruiting No phase listed Observational

OpalGenix- Personalized Postoperative Pain Management Following Lumbar Spinal Fusion and Decompression Surgery in Adults

NCT05452694
View directory record Official record
Conditions
Lumbar Spine Stenosis, Lumbar Spine Degeneration
Interventions
Not listed
Lead sponsor
OpalGenix, Inc
Industry
Eligibility
18 Years to 99 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities

NCT00403455
View directory record Official record
Conditions
PTSD
Interventions
Paroxetine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 21, 2026, 5:32 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Personalized Post-Operative Pain Management

NCT06669650
View directory record Official record
Conditions
Persistent Post Operative Opioid Use, Post-surgical Pain
Interventions
PGx guided personalized post-operative pain management, Oxycodone, Hydromorphone
Other · Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetics of Disulfiram for Cocaine

NCT00149630
View directory record Official record
Conditions
Cocaine Dependence, Opioid Dependence
Interventions
Disulfiram, Methadone, CBT, Lactose
Drug · Behavioral · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal

NCT00664404
View directory record Official record
Conditions
Smoking
Interventions
Functional Magnetic Resonance Imaging (fMRI)
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)

NCT01786967
View directory record Official record
Conditions
Urge Urinary Incontinence
Interventions
Fesoterodine Fumarate
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 21, 2026, 5:32 PM EDT